## Notice of References Cited

Application/Control No.

10/719,004

Examiner

Jeffrey S. Parkin, Ph.D.

Applicant(s)/Patent Under Reexamination HAIGWOOD, NANCY L.

Art Unit
Page 1 of 3

#### **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
_	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	ш	US-		·	
	F	US-			
	Ø	US-			
	Ξ	US-			
	_	US-			
	٦	US-			
	K	US-			
	L	US-			
	М	US-			

#### **FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	σ					
	R	· · · · · · · · · · · · · · · · · · ·				
	S					
	Т					

#### **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Song, B., et al., 2004, Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease, Virol. 322:168-181.
	٧	Quinones-Kochs, M. I., et al., 2002, Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein:effects on protein function and the neutralizing antibody response, J. Virol. 76(9):4199-4211.
	w	Teeraputon, S., et al., 2005, N-linked glycosylation in C2 region of HIV-1 envelope reduces sensitivity to neutralizing antibodies, Vir. Immunol. 18(2):343-353.
	х	Nishimura, Y., et al., 2004, Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses, Proc. Natl. Acad. Sci. 101(33):12324-12329.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

## Notice of References Cited

Application/Control No. 10/719,004	Reexamination	Applicant(s)/Patent Under Reexamination HAIGWOOD, NANCY L.		
Examiner	Art Unit			
leffrey S. Parkin, Ph.D.	1648	Page 2 of 3		

#### U.S. PATENT DOCUMENTS

	C.C. PATENT DOGGLERY					
*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification	
	А	US-				
	В	US-				
	С	US-				
	D	US-				
	E	US-				
	F	US-				
	G	US-				
	Н	US-				
	ı	US-				
	J	US-				
	к	US-				
,	L	US-				
	М	US-				

#### **FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					,
	0					
	Ρ					
	ø					
	R					
	s					
	Т					

#### **NON-PATENT DOCUMENTS**

	T	
*		Include as-applicable:-Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Gallo, R. C., 2005, The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years, The Lancet 366:1894-1898.
	V	Staprans, S. I., and M. B. Feinberg, 2004, The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines, Expert. Rev. Vaccines 3(4):S5-S32.
	w	Feinberg, M. B., and J. P. Moore, 2002, AIDS vaccine models:challenging challenge viruses, Nat. Med. 8(3):207-210.
	×	Moore, J. P., and D. R. Burton, 1999, HIV-1 neutralizing antibodies:how full is the bottle?, Nat. Med. 5(2):142-144.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

# Notice of References Cited

Application/Control No.

10/719,004

Examiner

Jeffrey S. Parkin, Ph.D.

Applicant(s)/Patent Under
Reexamination
HAIGWOOD, NANCY L.

Art Unit
Page 3 of 3

## U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	Ε	US-			
	F	US-			
	G	US-			
	Τ	US-			
	1	US-			
	7	US-			
	K	US-			
	L	US-	· ·		
	М	US-			

#### **FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					,
	Р					
	σ					
	R					
	S					
	Т					

### **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Piguet, V., and D. Trono, 2001, Living in oblivion:HIV immune evasion, Sem. Immunol. 13:51-57.
	V	Mooij, P., and J. L. Heeney, 2001, Rational development of prophylactic HIV vaccines based on structural and regulatory proteins, Vaccine 20:304-321.
	w	Haynes, B. F., 1996, HIV vaccines:where we are and where we are going, The Lancet 348:933-937.
	x	Kohler, H., et al., 1992, Clonal dominance:cause for a limited and failing immune response to HIV-1 infection and vaccination, J. Acquir. Immune Defic. Syndr. 5:1158-1168.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.